Header Logo

Connection

KEVIN GAREY to Bacterial Toxins

Back to Details
This is a "connection" page, showing publications KEVIN GAREY has written about Bacterial Toxins.
KEVIN GAREY
Connection Strength
3.828
Bacterial Toxins
  1. Molecular epidemiology of toxigenic Clostridioides difficile isolates from hospitalized patients and the hospital environment in Dhaka, Bangladesh. Anaerobe. 2020 Feb; 61:102081.
    View in: PubMed
    Score: 0.610
  2. Multiplex Real-Time PCR Method for Simultaneous Identification and Toxigenic Type Characterization of Clostridium difficile From Stool Samples. Ann Lab Med. 2015 May; 35(3):306-13.
    View in: PubMed
    Score: 0.452
  3. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother. 2008 Dec; 20(6):714-20.
    View in: PubMed
    Score: 0.291
  4. Baseline stool toxin concentration is associated with risk of recurrence in children with Clostridioides difficile infection. Infect Control Hosp Epidemiol. 2023 09; 44(9):1403-1409.
    View in: PubMed
    Score: 0.194
  5. Higher In Vivo Fecal Concentrations of Clostridioides difficile Toxins A and B in Patients With North American Pulsed-Field Gel Electrophoresis Type 1/Ribotype 027 Strain Infection. Clin Infect Dis. 2022 11 30; 75(11):2019-2022.
    View in: PubMed
    Score: 0.192
  6. Stool Toxin Concentration Does Not Distinguish Clostridioides difficile Infection from Colonization in Children Less Than 3 Years of Age. J Pediatric Infect Dis Soc. 2022 Oct 25; 11(10):454-458.
    View in: PubMed
    Score: 0.191
  7. Ultrasensitive and Quantitative Toxin Measurement Correlates With Baseline Severity, Severe Outcomes, and Recurrence Among Hospitalized Patients With Clostridioides difficile Infection. Clin Infect Dis. 2022 07 06; 74(12):2142-2149.
    View in: PubMed
    Score: 0.187
  8. Comparative clinical outcomes evaluation of hospitalized patients infected with Clostridioides difficile ribotype 106 vs. other toxigenic strains. Anaerobe. 2021 Dec; 72:102440.
    View in: PubMed
    Score: 0.176
  9. Clostridioides difficile Infection in Cancer and Immunocompromised Patients: Relevance of a Two-step Diagnostic Algorithm and Infecting Ribotypes on Clinical Outcomes. Clin Infect Dis. 2021 05 18; 72(10):e460-e465.
    View in: PubMed
    Score: 0.173
  10. Absence of Toxemia in Clostridioides difficile Infection: Results from Ultrasensitive Toxin Assay of Serum. Dig Dis Sci. 2021 10; 66(10):3303-3306.
    View in: PubMed
    Score: 0.167
  11. Toxin A-Predominant Pathogenic Clostridioides difficile: A Novel Clinical Phenotype. Clin Infect Dis. 2020 06 10; 70(12):2628-2633.
    View in: PubMed
    Score: 0.162
  12. Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes. Antimicrob Agents Chemother. 2016 06; 60(6):3519-23.
    View in: PubMed
    Score: 0.122
  13. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin. Ann Clin Microbiol Antimicrob. 2016 Apr 12; 15:22.
    View in: PubMed
    Score: 0.121
  14. Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection. J Antimicrob Chemother. 2016 May; 71(5):1245-51.
    View in: PubMed
    Score: 0.120
  15. Identification of toxemia in patients with Clostridium difficile infection. PLoS One. 2015; 10(4):e0124235.
    View in: PubMed
    Score: 0.113
  16. Investigation of potentially pathogenic Clostridium difficile contamination in household environs. Anaerobe. 2014 Jun; 27:31-3.
    View in: PubMed
    Score: 0.105
  17. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas. J Clin Pathol. 2010 Apr; 63(4):355-8.
    View in: PubMed
    Score: 0.080
  18. Association of interleukin-8 polymorphism and immunoglobulin G anti-toxin A in patients with Clostridium difficile-associated diarrhea. Clin Gastroenterol Hepatol. 2007 Aug; 5(8):964-8.
    View in: PubMed
    Score: 0.066
  19. Epidemiology and incidence of Clostridium difficile-associated diarrhoea diagnosed upon admission to a university hospital. J Hosp Infect. 2007 Jan; 65(1):42-6.
    View in: PubMed
    Score: 0.063
  20. Prevalence of diarrhea at a university hospital and association with modifiable risk factors. Ann Pharmacother. 2006 Jun; 40(6):1030-4.
    View in: PubMed
    Score: 0.061
  21. A quantitative PCR to detect non-toxigenic Clostridioides difficile. Microbiol Spectr. 2025 Jan 07; 13(1):e0160824.
    View in: PubMed
    Score: 0.055
  22. Stool Interleukin-1? Differentiates Clostridioides difficile Infection (CDI) From Asymptomatic Carriage and Non-CDI Diarrhea. Clin Infect Dis. 2023 02 08; 76(3):e1467-e1475.
    View in: PubMed
    Score: 0.049
  23. Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis. Am J Physiol Gastrointest Liver Physiol. 2020 05 01; 318(5):G870-G888.
    View in: PubMed
    Score: 0.040
  24. Clostridioides difficile ribotypes isolated from domestic environment and from patients in Bangladesh. Anaerobe. 2019 Apr; 56:88-90.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.